AU2018326721B2 - Compounds and compositions for IRE1 inhibition - Google Patents

Compounds and compositions for IRE1 inhibition Download PDF

Info

Publication number
AU2018326721B2
AU2018326721B2 AU2018326721A AU2018326721A AU2018326721B2 AU 2018326721 B2 AU2018326721 B2 AU 2018326721B2 AU 2018326721 A AU2018326721 A AU 2018326721A AU 2018326721 A AU2018326721 A AU 2018326721A AU 2018326721 B2 AU2018326721 B2 AU 2018326721B2
Authority
AU
Australia
Prior art keywords
amino
pyrazin
imidazo
naphthalen
cyclohex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018326721A
Other languages
English (en)
Other versions
AU2018326721A1 (en
Inventor
Bradley J. Backes
George Hynd
Richard M. Keenan
Jamie Knight
Dustin J. MALY
Scott A. OAKES
Feroz R. PAPA
Charles Reynolds
Jon Sutton
Ben Whittaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Optikira LLC
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Optikira LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD, Optikira LLC filed Critical University of California Berkeley
Publication of AU2018326721A1 publication Critical patent/AU2018326721A1/en
Application granted granted Critical
Publication of AU2018326721B2 publication Critical patent/AU2018326721B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018326721A 2017-09-01 2018-08-31 Compounds and compositions for IRE1 inhibition Active AU2018326721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (2)

Publication Number Publication Date
AU2018326721A1 AU2018326721A1 (en) 2020-03-12
AU2018326721B2 true AU2018326721B2 (en) 2022-12-01

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018326721A Active AU2018326721B2 (en) 2017-09-01 2018-08-31 Compounds and compositions for IRE1 inhibition

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
MX2021010345A (es) * 2019-02-27 2021-12-15 Optikira Llc Compuestos de pirazolopiridina para la inhibición de ire1.
CA3131386A1 (en) * 2019-02-27 2020-09-03 Richard Keenan Imidazolopyrazine compounds for ire1 inhibition
CA3188602A1 (en) * 2020-08-07 2022-02-10 Richard Keenan Pyrazolopyridine compounds and methods of inhibiting ire1 using same
CN116583276A (zh) * 2020-11-13 2023-08-11 加利福尼亚大学董事会 IRE1α抑制剂及其用途
EP4460492A1 (en) * 2022-01-07 2024-11-13 (INSERM) Institut National de la Santé et de la Recherche Médicale Compounds containing a hydroxyphenyl moiety and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
MX388981B (es) 2010-04-05 2025-03-20 Fosun Orinove Pharmatech Inc Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2017152117A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
US10934275B2 (en) 2016-12-02 2021-03-02 Cornell University IRE1 small molecule inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1

Also Published As

Publication number Publication date
KR20200066301A (ko) 2020-06-09
CA3074139A1 (en) 2019-03-07
CN111526877B (zh) 2023-08-25
IL272845B1 (en) 2023-08-01
EP3675858A2 (en) 2020-07-08
EP3675858A4 (en) 2021-03-17
EP3675858B1 (en) 2023-04-26
CN111526877A (zh) 2020-08-11
RU2020112425A3 (enExample) 2022-03-31
WO2019046711A3 (en) 2020-04-02
WO2019046711A2 (en) 2019-03-07
ZA202001320B (en) 2023-10-25
US20200354367A1 (en) 2020-11-12
RU2020112425A (ru) 2021-10-04
BR112020004226A2 (pt) 2020-11-17
JP2020532589A (ja) 2020-11-12
AU2018326721A1 (en) 2020-03-12
IL272845A (en) 2020-04-30
MX2020002322A (es) 2020-10-05
US11649237B2 (en) 2023-05-16
SG11202001609RA (en) 2020-03-30
IL272845B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
AU2018326721B2 (en) Compounds and compositions for IRE1 inhibition
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
ES2893289T3 (es) Inhibidores de glucosidasa
WO2019204354A1 (en) Spirocyclic compounds
US9096614B2 (en) Therapeutically active thiazolo-pyrimidine derivatives
AU2018420231B2 (en) Phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor
CA3108809C (en) Heteroaromatic compounds, pharmaceutical compositions and uses thereof
WO2014165090A1 (en) Compounds for the treatment of tuberculosis
US11149008B2 (en) Sulfamide derivatives and preparation method and use thereof
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
US20190263828A1 (en) Heteroaromatic compounds as vanin inhibitors
US9951061B2 (en) CaMKII inhibitors and uses thereof
TW202023550A (zh) 作為vanin抑制劑之雜芳族化合物
US20220048889A1 (en) Heteroaromatic compounds as vanin inhibitors
KR20250149802A (ko) Akt1의 공유결합 변형제 및 이의 용도
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
WO2017073743A1 (ja) 三環性化合物
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4011880A1 (en) Jak kinase inhibitor and use thereof
CN103435562B (zh) 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
WO2017021216A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
US20220194945A1 (en) Imidazolopyridine Compounds For IRE1 Inhibition
TW202313635A (zh) 巨環化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)